Activity index | Time | Mean ± SD change from the baseline | |
---|---|---|---|
Kunxian, n = 35 | Placebo, n = 33 | ||
BASDAI (0–10), mean (±SD) | Week 2 | -1.46 ± 1.61 | -0.91 ± 1.31 |
Week 6 | -1.98 ± 1.48a | -0.10 ± 1.13 | |
Week 12 | -1.68 ± 1.70 | -1.11 ± 1.17 | |
BASFI (0–10), mean (±SD) | Week 2 | -0.52 ± 1.17 | -0.15 ± 1.32 |
Week 6 | -0.88 ± 1.18c | -0.28 ± 1.27 | |
Week 12 | -0.75 ± 2.26 | -0.01 ± 1.59 | |
ASDAS-CRP, mean (±SD) | Week 2 | -0.84 ± 0.91b | -0.05 ± 0.98 |
Week 6 | -1.25 ± 0.95a | -0.06 ± 0.70 | |
Week 12 | -1.08 ± 1.03b | -0.11 ± 1.79 | |
ESR (mm/h), mean (±SD) | Week 2 | -11.26 ± 16.38c | 0.15 ± 9.48 |
Week 6 | -16.26 ± 18.63b | 0.71 ± 16.76 | |
Week 12 | -14.51 ± 22.65c | 0.09 ± 16.50 | |
CRP (ref 6 mg/l), mean (±SD) | Week 2 | -16.49 ± 21.12b | 0.37 ± 16.55 |
Week 6 | -20.66 ± 23.71b | 1.07 ± 20.20 | |
Week12 | -18.50 ± 26.18c | 0.76 ± 16.67 | |
Level of morning stiffness, 0–10 cm VAS | Week2 | -2.56 ± 2.81c | -0.88 ± 1.37 |
Week6 | -2.10 ± 2.39c | -0.78 ± 2.38 | |
Week 12 | -2.53 ± 2.60c | -1.34 ± 1.67 | |
Global assessment, 0–10 cm VAS | Week 2 | -1.29 ± 1.94 | -0.54 ± 1.30 |
Week 6 | -1.99 ± 2.10c | -0.81 ± 1.31 | |
Week 12 | -1.69 ± 2.30 | -0.85 ± 1.55 | |
Total back pain, 0–10 cm VAS | Week 2 | -1.22 ± 1.99 | -0.45 ± 1.60 |
Week 6 | -1.97 ± 2.08c | --0.81 ± 1.98 | |
Week 12 | -1.94 ± 2.17c | -0.77 ± 1.57 | |
Swollen joints, range 0–44 | Week 2 | -0.14 ± 0.42 | 0.14 ± 0.85 |
Week 6 | -0.16 ± 0.5 | -0.05 ± 0.34 | |
Week 12 | 0 ± 0.82 | -0.06 ± 0.34 | |
Tender joints, range 0–44 | Week 2 | -1.19 ± 2.77 | -0.35 ± 0.73 |
Week 6 | -2.38 ± 3.66c | -0.26 ± 1.24 | |
Week 12 | -2.89 ± 3.43c | -0.36 ± 1.32 | |
BASMI (0–10), mean (±SD) | Week 2 | -0.32 ± 0.94 | -0.32 ± 0.97 |
Week 6 | -0.49 ± 1.10 | -0.14 ± 0.98 | |
Week 12 | -0.24 ± 1.09 | -0.21 ± 0.95 |